B · Normal
[The CRO concept is active and Wanbang Pharmaceutical rises by more than 12%] On September 14th, the CRO concept was active, and Wanbang Pharmaceutical rose by more than 12%. Nearshore Protein, Chengda Pharmaceutical, Hongbo Pharmaceutical, and Chengdu Pioneer followed suit. On the news, a CITIC Securities research report stated that new blockbuster drugs/new molecules/new technologies have increased requirements for process development and experimental design capabilities. China's CDMO industry is expected to enter an era driven by the dual core of "engineer dividends" + "leading innovation dividends" by virtue of the continuous accumulation of early pipelines in the global biomedical innovation technology field.
Comments